Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Arrowhead Research Corporation ("Arrowhead" or the "Company") (NASDAQ:ARWR). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by the Company between August 12, 2014 and October 8, 2014, concerning Arrowhead's operations and financial prospects.

Arrowhead is a biopharmaceutical company engaged in the development of RNA Interference ("RNAi") therapeutics that will suppress disease-causing genes. The Company's RNAi therapeutic ARC-520 is currently being tested for its effectiveness in using RNAi to halt the production of hepatitis B genes.

The investigation is related to the Company's October 8, 2014, disclosure of the results of its Phase IIa study, which revealed that ARC-520 dosed at 2 mg/kg only induced a reduction in hepatitis B surface antigens that was far short of the levels previously suggested by the Company. Following this news, Arrowhead stock dropped $5.48 per share, or almost 44% below its previous closing price, to close at $7.03 per share on October 8, 2014, on extraordinary volume.

If you purchased Arrowhead shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

Copyright Business Wire 2010